LOXL2 and colorectal carcinoma: LOXL2 was shown to promote fibronectin production, MMP9 and CXCL12 expression and BMDCs recruitment to assist PMN formation [288], whereas a randomized phase 2 trials showed that simtuzumab, an antibody to LOXL2, did not improve clinical outcomes in patients with metastatic KRAS mutant colorectal carcinoma [259] or metastatic pancreatic adenocarcinoma [260].